

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal

### Equality impact assessment – Scoping

#### **Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

- |   |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

During scoping consultation, it was noted that the scope should ensure a good representation of people from black, Asian and minority ethnic cultures and deprived areas of England and Wales. It was also noted that the scope should ensure equity of access to avelumab with axitinib on the NHS regardless of where the patient lives, for people with all subtypes of RCC, including RCC with sarcomatoid and rhabdoid features, and RCC brain metastases.
---

- |   |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

The committee will make decisions based on the evidence presented by the submitting company. It will take into account evidence for specific groups, and subtypes of RCC, in its decision making.
---

- |  |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

NA.
-----

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

NA.

**Approved by Associate Director (name):** Ross Dent

**Date:** 27/08/2024